| 1. |
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
|
|
| 5. |
- Watts, Eleanor L., et al.
(författare)
-
Circulating free testosterone and risk of aggressive prostate cancer : Prospective and Mendelian randomisation analyses in international consortia
- 2022
-
Ingår i: International Journal of Cancer. - : John Wiley & Sons. - 0020-7136 .- 1097-0215. ; 151:7, s. 1033-1046
-
Tidskriftsartikel (refereegranskat)abstract
- Previous studies had limited power to assess the associations of testosterone with aggressive disease as a primary endpoint. Further, the association of genetically predicted testosterone with aggressive disease is not known. We investigated the associations of calculated free and measured total testosterone and sex hormone-binding globulin (SHBG) with aggressive, overall and early-onset prostate cancer. In blood-based analyses, odds ratios (OR) and 95% confidence intervals (CI) for prostate cancer were estimated using conditional logistic regression from prospective analysis of biomarker concentrations in the Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group (up to 25 studies, 14 944 cases and 36 752 controls, including 1870 aggressive prostate cancers). In Mendelian randomisation (MR) analyses, using instruments identified using UK Biobank (up to 194 453 men) and outcome data from PRACTICAL (up to 79 148 cases and 61 106 controls, including 15 167 aggressive cancers), ORs were estimated using the inverse-variance weighted method. Free testosterone was associated with aggressive disease in MR analyses (OR per 1 SD = 1.23, 95% CI = 1.08-1.40). In blood-based analyses there was no association with aggressive disease overall, but there was heterogeneity by age at blood collection (OR for men aged <60 years 1.14, CI = 1.02-1.28; Phet =.0003: inverse association for older ages). Associations for free testosterone were positive for overall prostate cancer (MR: 1.20, 1.08-1.34; blood-based: 1.03, 1.01-1.05) and early-onset prostate cancer (MR: 1.37, 1.09-1.73; blood-based: 1.08, 0.98-1.19). SHBG and total testosterone were inversely associated with overall prostate cancer in blood-based analyses, with null associations in MR analysis. Our results support free testosterone, rather than total testosterone, in the development of prostate cancer, including aggressive subgroups.
|
|
| 6. |
- Clamp, A. R., et al.
(författare)
-
SCOTROC 2B : feasibility of carboplatin followed by docetaxel or docetaxel-irinotecan as first-line therapy for ovarian cancer
- 2006
-
Ingår i: British Journal of Cancer. - : Springer Science and Business Media LLC. - 0007-0920 .- 1532-1827. ; 94:1, s. 55-61
-
Tidskriftsartikel (refereegranskat)abstract
- The feasibility of combination irinotecan, carboplatin and docetaxel chemotherapy as first-line treatment for advanced epithelial ovarian carcinoma was assessed. One hundred patients were randomised to receive four 3-weekly cycles of carboplatin (area under the curve (AUC) 7) followed by four 3-weekly cycles of docetaxel 100 mg m(-2) (arm A, n=51) or docetaxel 60 mg m(-2) with irinotecan 200 mg m(-2) (arm B, n=49). Neither arm met the formal feasibility criterion of an eight-cycle treatment completion rate that was statistically greater than 60% (arm A 71% (90% confidence interval (CI) 58-81%; P=0.079; arm B 67% (90% CI 55-78%; P=0.184)). Median-dose intensities were >85% of planned dose for all agents. In arms A and B, 15.6 and 12.2% of patients, respectively, withdrew owing to treatment-related toxicity. Grade 3-4 sensory neurotoxicity was more common in arm A (1.9 vs 0%) and grade 3-4 diarrhoea was more common in arm B (0.6 vs 3.5%). Of patients with radiologically evaluable disease at baseline, 50 and 48% responded to therapy in arms A and B, respectively; at median 17.1 months' follow-up, median progression-free survival was 17.1 and 15.9 months, respectively. Although both arms just failed to meet the formal statistical feasibility criteria, the observed completion rates of around 70% were reasonable. The addition of irinotecan to first-line carboplatin and docetaxel chemotherapy was generally well tolerated although associated with increased gastrointestinal toxicity. Further exploratory studies of topoisomerase-I inhibitors in this setting may be warranted.
|
|
| 7. |
- Aramo-Immonen, Heli, 1964-, et al.
(författare)
-
Trust-related network collaboration : difficulties, potential and paradoxes
- 2010
-
Rapport (övrigt vetenskapligt/konstnärligt)abstract
- Tämä tutkimus on esiselvitys suomalaisen meriteollisuuden verkostotoiminnan tilasta. Tutkimuksen tavoitteena oli selvittää, mitä aihealueita meriklusterin verkoston toiminnassa kannattaisi jatkotutkia.Tutkimuksen aikana suoritettiin kaksi kohdennettua kyselytutkimusta meriklusterin verkoston toimijoille. Kyselyt lähetettiin 392:en sähköpostiosoitteeseen vuoden 2009 lopulla ja kakkosvaiheessa vuoden 2010 alkupuolella. Vastausprosentti tutkimuskyselyyn oli 12 %. Tutkimuksen suunnitteli ja tutkimuskysymykset laati Tampereen teknillisen yliopiston tuotantotalouden sekä tiedonhallinnan ja logistiikan laitoksen yhteinen tutkimusryhmä. Yoso Oy avusti kyselyn laatimisessa ja kyselytutkimuksen tulosten analysoinnissa. Kysely toteutettiin Yoso Oy:n Internet-pohjaisella kyselytyökalulla.Tutkimuksessa löytyi useita tutkimuksen kannalta mielenkiintoisia osa-alueita koskien verkoston toimintaa. Tässä raportissa julkaistaan tutkimuksen tulokset ja raportin lopussa pohditaan johtopäätöksiä tuloksista. Yleisesti voidaan todeta, että meriklusterin verkoston toiminta on suomalaisen meriteollisuuden kilpailukyvyn näkökulmasta avainasemassa. Verkoston kilpailukykyyn vaikuttavia havaittuja potentiaalisia tutkimusalueita ovat mm. miten verkostossa synnytetään ja vaalitaan kilpailukykyä edistäviä innovaatioita (liiketoiminta- sekä teknologiainnovaatiot), miten arvontuotossa ilmeneviä ongelmia verkostossa kommunikoidaan sekä esim. kilpailukykyisen toiminnan vaatiman integraation aste verkostossa. Verkoston tehokkuuteen ja tuottavuuteen vaikuttavia tutkimuksen arvoisia tekijöitä havaittiin olevan mm. toimintojen kypsyys, horisontaalinen ja vertikaalinen dynamiikka verkostossa sekä arvonmuodostuksen mekanismit. Tulevaisuuteen tähtäävän globaalin verkottuneen toiminnan näkökulmasta tutkimisen arvoista olisi mm. luottamuksen synnyttäminen virtuaalisessa verkostossa (toimijat ovat maantieteellisesti ja kulttuurisesti etäällä toisistaan), verkostotoiminnan kypsyys pk-sektorilla sekä arvontuottokyvykkyys verkoston välityksellä.
|
|
| 8. |
- Uusitalo, H., et al.
(författare)
-
Improved systemic safety and risk-benefit ratio of topical 0.1% timolol hydrogel compared with 0.5% timolol aqueous solution in the treatment of glaucoma
- 2006
-
Ingår i: Graefe's Archives for Clinical and Experimental Ophthalmology. - : Springer Science and Business Media LLC. - 0721-832X .- 1435-702X. ; 244:11, s. 1491-1496
-
Tidskriftsartikel (refereegranskat)abstract
- The purpose of the study was to compare the systemic safety and risk-benefit ratio of 0.1% timolol hydrogel and 0.5% aqueous timolol eye drops in the treatment of glaucoma. An 8-week randomised, double-blind, cross-over, multicentre study. A total of 25 patients with primary open-angle glaucoma, exfoliation glaucoma, or ocular hypertension was enrolled. After completing a wash-out period, patients were randomly chosen to receive either 0.1% timolol hydrogel once daily or 0.5% aqueous timolol eye drops twice daily. Intraocular pressure and heart rate during rest and exercise, head-up tilt test results, spirometry readings, and plasma concentrations of timolol were recorded. The risk-benefit ratio was determined by calculating the ratio between several heart rate endpoints and the change in intraocular pressure (IOP). The mean drug-induced change in the peak heart rate during exercise was -13.5 beats/min (SD 7.6) in the 0.5% aqueous timolol group and -5.1 beats/min (SD 6.7) in the 0.1% timolol hydrogel group (P < 0.001; 95% CI 4.06-12.18). There was no significant difference in the IOP-reducing efficacy between these compounds. The risk-benefit ratio was significantly improved when 0.1% timolol hydrogel was used, compared with 0.5% aqueous timolol in the exercise test. In the head-up tilt test the risk-benefit ratio was significantly improved at rest (P < 0.05), at 1 min (P < 0.05) and at 5 min (P < 0.001) after patients had received 0.1% timolol hydrogel. There were, however, no differences in spirometry readings. After patients had been treated with 0.1% timolol hydrogel, plasma concentrations of timolol were 1/6 (at peak) and 1/50 (at trough) of those of 0.5% aqueous timolol. Drug-induced changes in the peak heart rate, and head-up tilt test results as well as plasma concentrations of timolol, were significantly more pronounced after treatment with 0.5% aqueous timolol than with 0.1% timolol hydrogel. Because of the statistically similar IOP-reducing efficacy of these formulations the risk-benefit ratio was significantly improved when patients used 0.1% timolol hydrogel instead of 0.5% aqueous timolol.
|
|
